i'm meg turrell. >>> now to a story that the world is watching.n egypt air flight from paris to cairo disappeared from radar. 66 people were on board. terrorism is not being ruled out. hadly gamble in paris has more on the tragedy in the sky. >> the white house said it's too early to say what happened to egypt air flight 804. it originates here last night at charles de gaulle in paris around 11:00 p.m. and was expected around 3:15 a.m. in cairo. the flight never made it. it cost radar contact between 2:30 and 2:40 a.m.er over the southern mediterranean. greek authorities say the plane was swerving, doing a 360 degree turn before it plummeted out of radar. we understand now that from egyptian authorities they are refusing to say the plane is anything other than missing. they say until they see debris they won't say further. there were multiple reports throughout the day that debris was found, even a life vest 120 miles off the coast of crete. we have heard greek authorities say degree found didn't belong to flight 804 and the french also reacted st

he joins our meg turrell over at the smart board. i want to start off with the first question. are known as the one's been at the forefront of biotech m & a. when you look at a name like valeant, what do you think the options are at this point? where do you see it in two to five years? >> well, suddenly, i have no edge on this more than any of you. but looking at valeant, it's pretty clear to me that they need to do something about streamlining their business and reduce that. that's something everybody can see. their business has been put together for many years for a position. it doesn't make that much sense together. it would be highly reasonable the new management team will go through a series of transactions where they would sell off pieces. they'll decide what to keep that would be the core of the new business. they would reduce debt and go from there. all of that can amount to an outcome that is compatible with an appropriate growth in the stock price. i can't tell you, i'm not the expert, but i can tell you, joe papa is a very competent, experienced pharmaceutical execut

. >> and mega turrel has a special report on bio tech stocks. stay tuned for that.ke reese, "day to feel alive"♪ ♪jake reese, "day to feel alive"♪ ♪jake reese, "day to feel alive"♪ amazing sleep stays with you all day and all night. sleep number beds with sleepiq technology give you the knowledge to adjust for the best sleep ever. it's the semi-annual sale! save $500 on the memorial day special edition mattress with sleepiq technology. know better sleep. only at a sleep number store. >>> 25 minutes left with the dow down 42. shares of lowe's though, reported better than expected earnings. beat street estimates and surpassed home depot's 6.5% increase that was reported yesterday, kelly. >> so that remains a bright spot. what do you think of the market? >> well in the absence of any compelling news it seems to be trading more in emotion -- >> are you saying the fed mins are not compelling news. >> i think it is news but i don't think as compelling as people are making it out -- >> even though it changed the expectations of the rate hike and all that. >> look everybody

not quite stock therapy, more of an outpatient segment with meg turrell.e has the details. >> this is the week for the big decision for sarepta. by thursday the fda is set to decide on whether to approve the muscular distrophy drug. this has been a roller coaster ride over the last four years for this stock. the decision could come anytime up until then. analysts are putting the outer limits of where the stock could go at $3 and above $60. probably going to be somewhere in between there. won't necessarily be one or the other. most analysts don't think this drug gets approved. in that case, they think the stock goes below $10. if it does get approved, put people it at 15% to 20% chance of approval, they see it going to $50 or $60 a share. if there's something in between where they say there's a little bit of a delay but there's a path forward, maybe in the $20 to $30 a share range. some think it goes higher than that. this is giving everybody whiplash, even in the last year. look at some of the moves on the fda events. when they get the green light, it goes

and meg turrell knows which. when "fast money" returns. ♪ (music pl ♪ throughout) uh oh. what's up? ♪ does nobody use a turn signal anymore? ♪ >>> welcome back to "fast money." tanking on earnings, kayla tausche is at headquarters with the latest. what's behind the move? >> there was a surprise legal charge that the company optioned the quarter $50 million or 15 cents a share detracted after a private settlement with a st. louis professor. it was a lawsuit that had been outstanding for years. the company views it as a positive. but it essentially doubled the company's loss in the quarter. and it came as growth of revenue and payment volume while slowing slightly did still come in far above expectations. hardware revenue for the actual card readers was up 634%. and the company was actually able to raise guidance because they're on boarding bigger merchants and they're offering some of those merchants bigger loans. but dorsey, despite the stock's move and slowdown in revenue, he was optimistic about square, but we asked whether he can stop the divergence between the two companies he o